Transformation Capital

The firm focuses on growth-stage companies, typically those with $10 million to $50 million in revenue that have proven unit economics and a clear path to profitability. Transformation Capital often provides the first institutional capital to businesses that were previously bootstrapped or family-funded. This stage preference means it avoids both early-stage venture risk and late-stage pre-IPO pricing.

The firm does not invest in early-stage therapeutics, biotech, medical devices, or pre-revenue health-tech startups. Its mandate is confined to companies where technology is applied to operational and financial workflows within healthcare delivery — such as revenue cycle management, care coordination, and provider enablement — rather than drug discovery or hardware.

The firm's pipeline is built on founder relationships and thematic research rather than broad auction processes. By targeting companies that have operated profitably for years without institutional capital, Transformation Capital often enters negotiations as the sole institutional lead, structuring terms directly with founder-operators who value an operational partner over the highest nominal bid.

The firm deploys exclusively through direct investments, taking majority or significant minority equity positions in its portfolio companies. There is no public record of Transformation Capital acting as a fund-of-funds or making LP commitments to other managers — its model is built around board-level engagement in each holding.

Transformation Capital operates as a traditional private equity firm managing third-party capital through a drawdown fund structure, not as a single-family office. The firm raises committed capital from institutional limited partners — though specific LP names and fund sizes are not publicly disclosed — and deploys it within a defined investment period.